Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0114-0006 in Active Crohn's Disease
2012-002432-93Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing NNC0114-0006 with Placebo (2 arms). Primary endpoint: Change in Crohn's Disease Activity Index (CDAI). Started Sep 2012; status: completed.
02
Drugs
NNC0114-0000-0005
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2012-002432-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002432-93.